|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
50,296,000 |
Market
Cap: |
197.66(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$1.9 - $40.3 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Ventyx Biosciences is a clinical-stage biopharmaceutical company engaged in the development of therapies for patients living with inflammatory diseases and autoimmune disorders. Co.'s product candidate is VTX958, an oral, selective clinical-stage tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis and Crohn's disease, among other potential indications. In addition, Co. is developing VTX002, an oral, selective sphingosine 1 phosphate receptor 1 modulator for ulcerative colitis. Co.'s oral, selective and peripherally restricted NLRP3 inhibitor, VTX2735, has been designed to treat systemic inflammatory diseases, such as cardiovascular, hepatic, renal and rheumatologic diseases.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
9,019 |
90,800 |
3,658,056 |
6,036,052 |
Total Sell Value |
$48,733 |
$221,937 |
$58,860,328 |
$133,915,096 |
Total People Sold |
4 |
4 |
7 |
8 |
Total Sell Transactions |
4 |
7 |
64 |
103 |
End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Subramaniam Somu |
|
|
2024-04-12 |
4 |
D |
$0.00 |
$0 |
I/I |
(695,339) |
7,744,296 |
|
- |
|
Nsv Partners Iii Gp Llc |
10% Owner |
|
2024-04-12 |
4 |
D |
$0.00 |
$0 |
I/I |
(695,339) |
7,744,296 |
|
- |
|
Mohan Raju |
CEO AND PRESIDENT |
|
2024-04-02 |
4 |
S |
$5.40 |
$23,299 |
D/D |
(4,312) |
1,578,250 |
|
23% |
|
Auster Martin |
CHIEF FINANCIAL OFFICER |
|
2024-04-02 |
4 |
S |
$5.40 |
$7,592 |
D/D |
(1,405) |
24,303 |
|
23% |
|
Nuss John |
CHIEF SCIENTIFIC OFFICER |
|
2024-04-02 |
4 |
S |
$5.40 |
$8,921 |
D/D |
(1,651) |
264,998 |
|
23% |
|
Krueger Christopher W |
CHIEF BUSINESS OFFICER |
|
2024-04-02 |
4 |
S |
$5.40 |
$8,921 |
D/D |
(1,651) |
284,999 |
|
23% |
|
Nuss John |
CHIEF SCIENTIFIC OFFICER |
|
2024-03-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,531 |
266,649 |
|
- |
|
Auster Martin |
CHIEF FINANCIAL OFFICER |
|
2024-03-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,531 |
25,708 |
|
- |
|
Mohan Raju |
CEO AND PRESIDENT |
|
2024-03-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
11,843 |
1,582,562 |
|
- |
|
Krueger Christopher W |
CHIEF BUSINESS OFFICER |
|
2024-03-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,531 |
286,650 |
|
- |
|
Nuss John |
Chief Scientific Officer |
|
2023-12-20 |
4 |
S |
$2.12 |
$37,334 |
D/D |
(17,628) |
262,118 |
|
-95% |
|
Krueger Christopher W |
Chief Business Officer |
|
2023-12-20 |
4 |
S |
$2.12 |
$11,210 |
D/D |
(5,293) |
282,119 |
|
-95% |
|
Mohan Raju |
CEO and President |
|
2023-12-20 |
4 |
S |
$2.12 |
$124,660 |
D/D |
(58,860) |
1,570,719 |
|
-95% |
|
Mohan Raju |
CEO and President |
|
2023-12-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
116,668 |
1,629,579 |
|
- |
|
Krueger Christopher W |
Chief Business Officer |
|
2023-12-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,479 |
287,412 |
|
- |
|
Nuss John |
Chief Scientific Officer |
|
2023-12-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
34,931 |
279,746 |
|
- |
|
Nsv Partners Iii Gp Llc |
10% Owner |
|
2023-10-09 |
4 |
AS |
$30.03 |
$1,475,858 |
I/I |
(49,152) |
8,439,635 |
|
-92% |
|
Subramaniam Somu |
Director |
|
2023-10-09 |
4 |
AS |
$30.03 |
$1,475,858 |
I/I |
(49,152) |
8,439,635 |
|
-92% |
|
Mohan Raju |
Chief Executive Officer |
|
2023-10-05 |
4 |
AS |
$29.11 |
$873,231 |
D/D |
(30,000) |
1,512,911 |
|
-92% |
|
Mohan Raju |
Chief Executive Officer |
|
2023-10-05 |
4 |
OE |
$8.04 |
$241,200 |
D/D |
30,000 |
1,542,911 |
|
- |
|
Nuss John |
Chief Scientific Officer |
|
2023-10-03 |
4 |
AS |
$29.94 |
$299,933 |
D/D |
(10,000) |
244,815 |
|
-92% |
|
Nuss John |
Chief Scientific Officer |
|
2023-10-03 |
4 |
OE |
$0.20 |
$33,542 |
D/D |
10,000 |
254,815 |
|
- |
|
Krueger Christopher W |
Chief Business Officer |
|
2023-10-03 |
4 |
AS |
$29.93 |
$449,699 |
D/D |
(15,000) |
276,548 |
|
-92% |
|
Krueger Christopher W |
Chief Business Officer |
|
2023-10-03 |
4 |
OE |
$8.04 |
$120,600 |
D/D |
15,000 |
291,548 |
|
- |
|
Subramaniam Somu |
Director |
|
2023-09-18 |
4 |
AS |
$37.81 |
$2,142,634 |
I/I |
(56,665) |
8,488,787 |
|
-95% |
|
178 Records found
|
|
Page 1 of 8 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|